Form 4: Biomarin Pharmaceutical Executive Reports Stock Transaction
Insider Transaction (Form 4)
Gregory R Friberg, EVP, Chief R&D Officer of Biomarin Pharmaceutical Inc, reported a transaction in 4,086 shares of common stock on September 30, 2026.
Summary
- Tax/exercise-price withholding: disposed of 4,086 Common Stock at $60.00 ($245,160) on September 30, 2026; holds 47,732 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Gregory R Friberg — Officer (EVP, Chief R&D Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Tax/exercise-price withholding | Common Stock | 4,086 | $60 | $245.2K | 47,732 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Tax/exercise-price withholding (4,086 shares) |
Keywords
insider transaction, Form 4, BMRN, BIOMARIN PHARMACEUTICAL INC, neutral, Gregory R Friberg
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.